rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Rani Therapeutics Holdings, Inc.

RANI · Nasdaq

Health CareBiotechnologyNot moving yet

RANI stood above a rising 150-day average in 19 of the last 52 weekly readings, and has been out of that trend for the last 31 weeks. It is 23.4% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 31
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$1.4M
Insider sales, 12 months
$602
Officials’ trades on record
0
Institutions holding
66 (-10)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 19 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$15.1M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months3
Sale orders, 12 months1
Buyers · sellers2 · 1
WhoDidSharesTraded
Mir A. ImranDirector, 10% ownerbought36,000at $0.6921 Jul 2026filed 23 Jul 2026
Talat ImranChief Executive Officerbought35,000at $0.719817 Jul 2026filed 21 Jul 2026
Alireza JavadiChief Technical Officersold386at $0.7827 Mar 2026filed 21 Jul 2026
Talat ImranChief Executive Officersold8,014at $1.4127 Dec 2024filed 21 Jul 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders66-10 on the quarter
New · exited9 · 19
Reported value$34.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
SAMSARA BIOCAPITAL, LLCadded · filed 14 Aug 202610,369,159$7.9M+1,869,159+22.0%
RA CAPITAL MANAGEMENT, L.P.unchanged · filed 14 Aug 20268,500,000$6.5M00.0%
AWM Investment Company, Inc.added · filed 14 Aug 20267,500,000$5.7M+1,000,000+15.4%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20264,611,257$3.5M-59,582−1.3%
Longaeva Partners L.P.unchanged · filed 14 Aug 20262,329,459$1.8M00.0%
Polar Asset Management Partners Inc.new · filed 14 Aug 20262,318,542$1.8M+2,318,542
Siren, L.L.C.unchanged · filed 13 Aug 20262,000,000$1.5M00.0%
ARMISTICE CAPITAL, LLCadded · filed 14 Aug 20261,859,057$278K+761,904+69.4%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026970,547$690K-187,132−16.2%
HEIGHTS CAPITAL MANAGEMENT, INCnew · filed 14 Aug 2026934,580$711K+934,580
31 Mar 2023 – 30 Jun 2026
315374Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Alireza Javadi Company insiderChief Technical Officer · last 27 Sep 20260 · 1
Talat Imran Company insiderChief Executive Officer · last 27 Sep 20266 · 1
Michelle Gilson Company insiderDirector · last 3 Aug 20260 · 0
Mir A. Imran Company insiderDirector, 10% owner · last 21 Jul 20262 · 1
Nicholas Maestas Company insiderChief Financial Officer · last 17 Jul 20260 · 0
Kate McKinley Company insiderChief Business Officer · last 3 Jun 20261 · 0
Abraham Bassan Company insiderDirector · last 28 May 20260 · 0
Dennis A. Ausiello Company insiderDirector · last 28 May 20260 · 0
Jean Luc Butel Company insiderDirector · last 28 May 20261 · 0
Lisa Ann Rometty Company insiderDirector · last 28 May 20260 · 0
Vasudev Jaiprakash Bailey Company insiderDirector · last 28 May 20260 · 0
South Cone Investments Limited Partnership Company insider10% owner · last 21 Oct 202526 · 3

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-83.4%
Interest coverFY 2025 · to 31 Dec 2025-13.25×
Cash and equivalentsFY 2025 · to 31 Dec 2025$18.6M
Free cash flowFY 2025 · to 31 Dec 2025−$18.8M

Analyst forecasts

No analyst forecasts yet.